Please login to the form below

Not currently logged in

Disarm Therapeutics

This page shows the latest Disarm Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Lilly buys biotech firm Disarm Therapeutics for $135m

Lilly buys biotech firm Disarm Therapeutics for $135m

Deal could eventually be worth up to $1.36bn. Eli Lilly is set to acquire private biotech company Disarm Therapeutics for an initial upfront payment of $135m, with a focus on ... Disarm’s focus is on the development of a new class of disease-modifying

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts


Add my company
Thrive Agency

We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...

Latest intelligence

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
New Playbook Alert: Virtual Patient Engagement
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...